MultiQure（MQR）株式概要Pure Biologics S.A.はバイオ医薬品会社で、免疫腫瘍学、自己免疫学、希少神経疾患の分野における生物学的医薬品と非系統的治療法の研究開発に従事している。 詳細MQR ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6報酬過去5年間の収益は年間8.2%増加しました。 リスク分析キャッシュランウェイが1年未満である マイナスの株主資本 Polish市場と比較して、過去 3 か月間の株価の変動が非常に大きい過去1年間で株主の希薄化は大幅に進んだ +2 さらなるリスクすべてのリスクチェックを見るMQR Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW467,983 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA467,983 investors already sharing narrativesYour Fair ValuezłCurrent Pricezł3.14該当なし内在価値ディスカウントEst. Revenue$PastFuture-26m2m2016201920222025202620282031Revenue zł0.2Earnings zł0.04AdvancedSet Fair ValueView all narrativesMultiQure S.A. 競合他社Stem Cells SpinSymbol: WSE:SCSMarket cap: zł18.2mGenomtecSymbol: WSE:GMTMarket cap: zł60.9mMabionSymbol: WSE:MABMarket cap: zł122.2mgenXoneSymbol: WSE:GX1Market cap: zł18.8m価格と性能株価の高値、安値、推移の概要MultiQure過去の株価現在の株価zł3.1452週高値zł7.7752週安値zł1.35ベータ0.211ヶ月の変化45.71%3ヶ月変化n/a1年変化-52.71%3年間の変化-83.98%5年間の変化-96.82%IPOからの変化-86.29%最新ニュースお知らせ • Jun 04Pure Biologics S.A., Annual General Meeting, Jun 29, 2026Pure Biologics S.A., Annual General Meeting, Jun 29, 2026, at 11:00 Central European Standard Time.New Risk • Dec 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 118% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł6.6m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-zł18m). Earnings have declined by 8.3% per year over the past 5 years. Shareholders have been substantially diluted in the past year (118% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (zł33.2m market cap, or US$9.13m).お知らせ • Nov 11Pure Biologics S.A. to Report Q3, 2025 Results on Nov 14, 2025Pure Biologics S.A. announced that they will report Q3, 2025 results on Nov 14, 2025お知らせ • Aug 21Pure Biologics S.A. to Report First Half, 2025 Results on Sep 15, 2025Pure Biologics S.A. announced that they will report first half, 2025 results on Sep 15, 2025New Risk • Jun 01New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 23% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł14m free cash flow). Negative equity (-zł13m). Earnings have declined by 21% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (zł28.6m market cap, or US$7.64m). Minor Risk Shareholders have been diluted in the past year (23% increase in shares outstanding).New Risk • Apr 04New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: zł38.3m (US$9.80m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł10m free cash flow). Negative equity (-zł5.0m). Earnings have declined by 37% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (zł38.3m market cap, or US$9.80m). Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change).最新情報をもっと見るRecent updatesお知らせ • Jun 04Pure Biologics S.A., Annual General Meeting, Jun 29, 2026Pure Biologics S.A., Annual General Meeting, Jun 29, 2026, at 11:00 Central European Standard Time.New Risk • Dec 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 118% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł6.6m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-zł18m). Earnings have declined by 8.3% per year over the past 5 years. Shareholders have been substantially diluted in the past year (118% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (zł33.2m market cap, or US$9.13m).お知らせ • Nov 11Pure Biologics S.A. to Report Q3, 2025 Results on Nov 14, 2025Pure Biologics S.A. announced that they will report Q3, 2025 results on Nov 14, 2025お知らせ • Aug 21Pure Biologics S.A. to Report First Half, 2025 Results on Sep 15, 2025Pure Biologics S.A. announced that they will report first half, 2025 results on Sep 15, 2025New Risk • Jun 01New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 23% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł14m free cash flow). Negative equity (-zł13m). Earnings have declined by 21% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (zł28.6m market cap, or US$7.64m). Minor Risk Shareholders have been diluted in the past year (23% increase in shares outstanding).New Risk • Apr 04New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: zł38.3m (US$9.80m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł10m free cash flow). Negative equity (-zł5.0m). Earnings have declined by 37% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (zł38.3m market cap, or US$9.80m). Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change).お知らせ • Jun 05Pure Biologics S.A., Annual General Meeting, Jun 28, 2024Pure Biologics S.A., Annual General Meeting, Jun 28, 2024.New Risk • Jun 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 48% per year over the past 5 years. Revenue is less than US$1m (zł109k revenue, or US$28k). Market cap is less than US$10m (zł22.3m market cap, or US$5.66m). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Shareholders have been diluted in the past year (3.5% increase in shares outstanding).お知らせ • Jan 30+ 2 more updatesPure Biologics S.A. to Report First Half, 2024 Results on Sep 16, 2024Pure Biologics S.A. announced that they will report first half, 2024 results on Sep 16, 2024Reported Earnings • Nov 19Third quarter 2023 earnings released: zł2.36 loss per share (vs zł2.85 loss in 3Q 2022)Third quarter 2023 results: zł2.36 loss per share. Net loss: zł7.60m (loss widened 18% from 3Q 2022).Reported Earnings • Sep 03Second quarter 2023 earnings releasedSecond quarter 2023 results: Net loss: zł9.92m (loss widened 75% from 2Q 2022).Reported Earnings • May 21First quarter 2023 earnings released: zł2.29 loss per share (vs zł2.82 loss in 1Q 2022)First quarter 2023 results: zł2.29 loss per share. Net loss: zł7.04m (loss widened 11% from 1Q 2022).お知らせ • May 09Pure Biologics Spólka Akcyjna, Annual General Meeting, May 25, 2023Pure Biologics Spólka Akcyjna, Annual General Meeting, May 25, 2023, at 12:00 Central European Standard Time.お知らせ • Feb 03+ 3 more updatesPure Biologics Spólka Akcyjna to Report Q3, 2023 Results on Nov 15, 2023Pure Biologics Spólka Akcyjna announced that they will report Q3, 2023 results on Nov 15, 2023分析記事 • Dec 06Here's Why We're Watching Pure Biologics Spólka Akcyjna's (WSE:PUR) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Reported Earnings • Sep 18Second quarter 2022 earnings released: zł2.51 loss per share (vs zł1.63 loss in 2Q 2021)Second quarter 2022 results: zł2.51 loss per share (further deteriorated from zł1.63 loss in 2Q 2021). Revenue: zł6.41m (up zł6.34m from 2Q 2021). Net loss: zł5.66m (loss widened 55% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.分析記事 • Aug 14We Think Pure Biologics Spólka Akcyjna (WSE:PUR) Can Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although...分析記事 • Apr 30Will Pure Biologics Spólka Akcyjna (WSE:PUR) Spend Its Cash Wisely?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Reported Earnings • Apr 02Full year 2021 earnings released: zł5.22 loss per share (vs zł7.11 loss in FY 2020)Full year 2021 results: zł5.22 loss per share. Revenue: zł18.0m (up zł17.5m from FY 2020). Net loss: zł11.8m (flat on FY 2020). Over the next year, revenue is expected to shrink by 97% compared to a 155% growth forecast for the pharmaceuticals industry in Poland.分析記事 • Jan 03We Think Pure Biologics Spólka Akcyjna (WSE:PUR) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Reported Earnings • Nov 18Third quarter 2021 earnings released: zł2.02 loss per share (vs zł1.60 loss in 3Q 2020)Third quarter 2021 results: Net loss: zł4.28m (loss widened 62% from 3Q 2020).Reported Earnings • Sep 15Second quarter 2021 earnings released: zł1.63 loss per share (vs zł1.59 loss in 2Q 2020)Second quarter 2021 results: Net loss: zł3.66m (loss widened 39% from 2Q 2020).分析記事 • Apr 21We're Interested To See How Pure Biologics Spólka Akcyjna (WSE:PUR) Uses Its Cash Hoard To GrowWe can readily understand why investors are attracted to unprofitable companies. For example, Pure Biologics Spólka...Is New 90 Day High Low • Jan 11New 90-day high: zł131The company is up 45% from its price of zł90.00 on 13 October 2020. The Polish market is up 20% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 32% over the same period.Reported Earnings • Nov 16Third quarter 2020 earnings released: zł1.60 loss per shareThird quarter 2020 results: Net loss: zł2.64m (loss widened 180% from 3Q 2019).Is New 90 Day High Low • Oct 29New 90-day low: zł73.80The company is down 26% from its price of zł100.00 on 30 July 2020. The Polish market is down 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period.Is New 90 Day High Low • Sep 24New 90-day low: zł91.00The company is down 10.0% from its price of zł101 on 26 June 2020. The Polish market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 44% over the same period.株主還元MQRPL BiotechsPL 市場7D11.7%0.9%1.7%1Y-52.7%-10.0%31.0%株主還元を見る業界別リターン: MQR過去 1 年間で-10 % の収益を上げたPolish Biotechs業界を下回りました。リターン対市場: MQRは、過去 1 年間で31 % のリターンを上げたPolish市場を下回りました。価格変動Is MQR's price volatile compared to industry and market?MQR volatilityMQR Average Weekly Movement17.1%Biotechs Industry Average Movement6.0%Market Average Movement4.9%10% most volatile stocks in PL Market10.3%10% least volatile stocks in PL Market3.0%安定した株価: MQRの株価は、 Polish市場と比較して過去 3 か月間で変動しています。時間の経過による変動: MQRの weekly volatility ( 17% ) は過去 1 年間安定していますが、依然としてPolishの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト20107Filip Jelenpurebiologics.comPure Biologics S.A.はバイオ医薬品会社で、免疫腫瘍学、自己免疫学、希少神経疾患の分野における生物学的医薬品および非系統的療法の研究開発に従事している。抗体やアプタマーの製造、精製、分析、特性評価、アッセイの設計、開発、検証を行うほか、活性分子を選択する技術プラットフォームの研究も行っている。同社は、治療・診断用修飾アプタマーをin vitroで選択するためのモジュール型プラットフォームPureAptaを提供している。また、視神経脊髄炎や重症筋無力症などの神経学的自己免疫疾患を患う患者の治療に使用する非全身療法の開発、製薬会社やバイオテクノロジー企業への受託研究も行っている。Pure Biologics S.A.は2010年に設立され、ポーランドのヴロツワフに本社を置いている。もっと見るMultiQure S.A. 基礎のまとめMultiQure の収益と売上を時価総額と比較するとどうか。MQR 基礎統計学時価総額zł38.45m収益（TTM）-zł9.10m売上高(TTM)n/a0.0xP/Sレシオ-4.2xPER（株価収益率MQR は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計MQR 損益計算書（TTM）収益zł0売上原価zł26.00k売上総利益-zł26.00kその他の費用zł9.07m収益-zł9.10m直近の収益報告Mar 31, 2026次回決算日Sep 30, 2026一株当たり利益（EPS）-0.74グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率-100.3%MQR の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/12 00:50終値2026/08/12 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋MultiQure S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Sylwia JaskiewiczDom Maklerski Banku Ochrony Srodowiska S.A.
お知らせ • Jun 04Pure Biologics S.A., Annual General Meeting, Jun 29, 2026Pure Biologics S.A., Annual General Meeting, Jun 29, 2026, at 11:00 Central European Standard Time.
New Risk • Dec 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 118% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł6.6m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-zł18m). Earnings have declined by 8.3% per year over the past 5 years. Shareholders have been substantially diluted in the past year (118% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (zł33.2m market cap, or US$9.13m).
お知らせ • Nov 11Pure Biologics S.A. to Report Q3, 2025 Results on Nov 14, 2025Pure Biologics S.A. announced that they will report Q3, 2025 results on Nov 14, 2025
お知らせ • Aug 21Pure Biologics S.A. to Report First Half, 2025 Results on Sep 15, 2025Pure Biologics S.A. announced that they will report first half, 2025 results on Sep 15, 2025
New Risk • Jun 01New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 23% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł14m free cash flow). Negative equity (-zł13m). Earnings have declined by 21% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (zł28.6m market cap, or US$7.64m). Minor Risk Shareholders have been diluted in the past year (23% increase in shares outstanding).
New Risk • Apr 04New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: zł38.3m (US$9.80m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł10m free cash flow). Negative equity (-zł5.0m). Earnings have declined by 37% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (zł38.3m market cap, or US$9.80m). Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change).
お知らせ • Jun 04Pure Biologics S.A., Annual General Meeting, Jun 29, 2026Pure Biologics S.A., Annual General Meeting, Jun 29, 2026, at 11:00 Central European Standard Time.
New Risk • Dec 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 118% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł6.6m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-zł18m). Earnings have declined by 8.3% per year over the past 5 years. Shareholders have been substantially diluted in the past year (118% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (zł33.2m market cap, or US$9.13m).
お知らせ • Nov 11Pure Biologics S.A. to Report Q3, 2025 Results on Nov 14, 2025Pure Biologics S.A. announced that they will report Q3, 2025 results on Nov 14, 2025
お知らせ • Aug 21Pure Biologics S.A. to Report First Half, 2025 Results on Sep 15, 2025Pure Biologics S.A. announced that they will report first half, 2025 results on Sep 15, 2025
New Risk • Jun 01New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 23% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł14m free cash flow). Negative equity (-zł13m). Earnings have declined by 21% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (zł28.6m market cap, or US$7.64m). Minor Risk Shareholders have been diluted in the past year (23% increase in shares outstanding).
New Risk • Apr 04New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: zł38.3m (US$9.80m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł10m free cash flow). Negative equity (-zł5.0m). Earnings have declined by 37% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (zł38.3m market cap, or US$9.80m). Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change).
お知らせ • Jun 05Pure Biologics S.A., Annual General Meeting, Jun 28, 2024Pure Biologics S.A., Annual General Meeting, Jun 28, 2024.
New Risk • Jun 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 48% per year over the past 5 years. Revenue is less than US$1m (zł109k revenue, or US$28k). Market cap is less than US$10m (zł22.3m market cap, or US$5.66m). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Shareholders have been diluted in the past year (3.5% increase in shares outstanding).
お知らせ • Jan 30+ 2 more updatesPure Biologics S.A. to Report First Half, 2024 Results on Sep 16, 2024Pure Biologics S.A. announced that they will report first half, 2024 results on Sep 16, 2024
Reported Earnings • Nov 19Third quarter 2023 earnings released: zł2.36 loss per share (vs zł2.85 loss in 3Q 2022)Third quarter 2023 results: zł2.36 loss per share. Net loss: zł7.60m (loss widened 18% from 3Q 2022).
Reported Earnings • Sep 03Second quarter 2023 earnings releasedSecond quarter 2023 results: Net loss: zł9.92m (loss widened 75% from 2Q 2022).
Reported Earnings • May 21First quarter 2023 earnings released: zł2.29 loss per share (vs zł2.82 loss in 1Q 2022)First quarter 2023 results: zł2.29 loss per share. Net loss: zł7.04m (loss widened 11% from 1Q 2022).
お知らせ • May 09Pure Biologics Spólka Akcyjna, Annual General Meeting, May 25, 2023Pure Biologics Spólka Akcyjna, Annual General Meeting, May 25, 2023, at 12:00 Central European Standard Time.
お知らせ • Feb 03+ 3 more updatesPure Biologics Spólka Akcyjna to Report Q3, 2023 Results on Nov 15, 2023Pure Biologics Spólka Akcyjna announced that they will report Q3, 2023 results on Nov 15, 2023
分析記事 • Dec 06Here's Why We're Watching Pure Biologics Spólka Akcyjna's (WSE:PUR) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Reported Earnings • Sep 18Second quarter 2022 earnings released: zł2.51 loss per share (vs zł1.63 loss in 2Q 2021)Second quarter 2022 results: zł2.51 loss per share (further deteriorated from zł1.63 loss in 2Q 2021). Revenue: zł6.41m (up zł6.34m from 2Q 2021). Net loss: zł5.66m (loss widened 55% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
分析記事 • Aug 14We Think Pure Biologics Spólka Akcyjna (WSE:PUR) Can Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although...
分析記事 • Apr 30Will Pure Biologics Spólka Akcyjna (WSE:PUR) Spend Its Cash Wisely?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Reported Earnings • Apr 02Full year 2021 earnings released: zł5.22 loss per share (vs zł7.11 loss in FY 2020)Full year 2021 results: zł5.22 loss per share. Revenue: zł18.0m (up zł17.5m from FY 2020). Net loss: zł11.8m (flat on FY 2020). Over the next year, revenue is expected to shrink by 97% compared to a 155% growth forecast for the pharmaceuticals industry in Poland.
分析記事 • Jan 03We Think Pure Biologics Spólka Akcyjna (WSE:PUR) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Reported Earnings • Nov 18Third quarter 2021 earnings released: zł2.02 loss per share (vs zł1.60 loss in 3Q 2020)Third quarter 2021 results: Net loss: zł4.28m (loss widened 62% from 3Q 2020).
Reported Earnings • Sep 15Second quarter 2021 earnings released: zł1.63 loss per share (vs zł1.59 loss in 2Q 2020)Second quarter 2021 results: Net loss: zł3.66m (loss widened 39% from 2Q 2020).
分析記事 • Apr 21We're Interested To See How Pure Biologics Spólka Akcyjna (WSE:PUR) Uses Its Cash Hoard To GrowWe can readily understand why investors are attracted to unprofitable companies. For example, Pure Biologics Spólka...
Is New 90 Day High Low • Jan 11New 90-day high: zł131The company is up 45% from its price of zł90.00 on 13 October 2020. The Polish market is up 20% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 32% over the same period.
Reported Earnings • Nov 16Third quarter 2020 earnings released: zł1.60 loss per shareThird quarter 2020 results: Net loss: zł2.64m (loss widened 180% from 3Q 2019).
Is New 90 Day High Low • Oct 29New 90-day low: zł73.80The company is down 26% from its price of zł100.00 on 30 July 2020. The Polish market is down 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period.
Is New 90 Day High Low • Sep 24New 90-day low: zł91.00The company is down 10.0% from its price of zł101 on 26 June 2020. The Polish market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 44% over the same period.
